Achieve Life Sciences Stock Forecast
NASDAQ: ACHVHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
Market open · Delayed 15 min · as of Oct 8, 11:57 AM ET
ACHV analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$14.15+99.58%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Achieve Life Sciences (2026-10-08), 12 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $14.15, with a high estimate of $21.00 and a low estimate of $9.00. The average target implies upside of 99.6% from the current price of $7.09.
The spread between the highest and lowest targets is 133.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ACHV.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 25% |
| Buy | 9 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $9.00 | +26.94% |
| Average target | $14.15 | +99.58% |
| High target | $21.00 | +196.19% |